These tumors grow and spread more slowly than HER2-positive breast cancer. Targeted immunotherapy drugs such as atezolizumab, pembrolizumab and trastuzumab deruxtecan are being increasingly used for treatment of HER-2 negative breast cancer as they have shown promising results with manageable safety profiles. The global HER-2 Negative Breast Cancer Market is estimated to be valued at US$ 15982.51 Bn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising adoption of targeted immunotherapy drugs is one of the key trends being witnessed in the Global HER-2 Negative Breast Cancer Market Size. Immunotherapy drugs such as trastuzumab deruxtecan and atezolizumab are more effective in treating triple-negative breast cancer, which accounts for 15-20% of all breast cancer cases and lacks expression of estrogen and progesterone receptors along with HER2 receptors. These drugs activate the immune system of the body to fight against cancer cells. With recent positive clinical trial results, the usage of immunotherapy drugs is growing for HER-2 negative breast cancer management. This increasing reliance on targeted immunotherapy medications is expected to propel market growth over the forecast period.
Segment Analysis
The global HER-2 negative breast cancer market is segmented on the basis of therapy, end user and region. By therapy, the market is segmented into chemotherapy, targeted therapy, hormonal therapy and others. The chemotherapy segment dominates the global market owing to high adoption and availability of generic drugs. The targeted therapy segment is expected to witness high growth during the forecast period due to ongoing research and development activities for novel targeted therapies.
Key Takeaways
The global HER-2 negative breast cancer market is expected to witness high growth during the forecast period of 2024-2031. The market size for 2024 is US$ 15982.51 Bn.
Regional analysis: North America dominates the global HER-2 negative breast cancer market and is expected to continue its dominance during the forecast period. This is attributed to the growing prevalence of breast cancer, availability of advanced healthcare facilities, and presence of key pharmaceutical companies in the region. Asia Pacific region is expected to witness fastest growth owing to growing awareness, improving healthcare infrastructure and increasing healthcare spending in the region.
Key players operating in the HER-2 negative breast cancer market are Robert Bosch GmbH (Germany), HELLA KGaA (Germany), Continental AG (Germany), Denso Corporation (Japan), Delphi Automotive PLC (U.K.), Autoliv Inc. (Sweden), and Valeo S.A. (France). Infineon Technologies AG (Germany) is another prominent player in the semiconductor industry primarily focused on sensor solutions for advanced driver-assistance systems and autonomous driving.
Get More Insights On This Topic: https://www.newsstatix.com/her-2-negative-breast-cancer-market-size-share-analysis-2023-2030/
Comments
0 comment